Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06761612 · ClinicalTrials.gov registry record

Retail COVID-19 Study

A clinical trial of COVID-19, sponsored by Biomedical Advanced Research and Development Authority.

Active
Registry status
2,660
Enrollment target
20
Study locations

NCT06761612: Active study of COVID-19, sponsored by Biomedical Advanced Research and Development Authority.

NCT06761612 is a study of COVID-19 that is active but no longer recruiting, run by Biomedical Advanced Research and Development Authority. The registered enrollment target is 2,660 participants, below the 38,456-participant average among 298 other COVID-19 trials with a reported enrollment target (93% lower). The trial reports 20 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06761612, a study of COVID-19, is active but no longer recruiting, sponsored by Biomedical Advanced Research and Development Authority.

ACTIVE NOT RECRUITING
Registry status
2,660 participants
Enrollment target
20
Study locations

Study Summary

Despite the availability of vaccines, there remains a need to identify specific immune responses that correlate with protection against SARS-CoV-2 infection. Additionally, the operational capability of retail pharmacy infrastructure to collect longitudinal data and biological samples needs to be assessed. This study aims to fill these gaps by determining correlates of protection (CoP), assessing the infrastructure's capability, and examining demographic and geographic differences in participation.

Primary Outcome

Correlates of Protective Immunity

Conditions Studied

COVID-19

Interventions

  • BIOLOGICAL FDA approved mRNA vaccines

Study Locations (20)

Texas

  • Walgreens - 420 N Frazier St - Conroe
  • Walgreens - 1919 W Gray St - Houston
  • Walgreens - 7440 FM 1960 Rd E - Humble
  • Walgreens - 8430 Broadway St - Pearland
  • Walgreens - 3316 Avenue H - Rosenberg

Illinois

  • Walgreens - 1554 E 55th St - Chicago
  • Walgreens - 4385 S Archer Ave - Chicago
  • Walgreens - 811 Madison St - Oak Park
  • Walgreens - 7251 Lake St - River Forest

Missouri

  • Walgreens - 17811 E US Highway 24 - Independence
  • Walgreens - 3845 Broadway Blvd - Kansas City
  • Walgreens - 2630 NE Vivion - Kansas City

Kansas

  • Walgreens - 15100 W 87th Street Pkwy - Lenexa
  • Walgreens - 7500 Metcalf Ave - Overland Park

Nevada

  • Walgreens - 6401 W Charleston Blvd - Las Vegas
  • Walgreens - 1445 W Craig Rd - North Las Vegas

New Jersey

  • Walgreens - 3218 Atlantic Ave - Atlantic City
  • Walgreens - 520 Convery Blvd - Perth Amboy

Florida

  • Walgreens - 3298 S John Young Pkwy - Kissimmee

Massachusetts

  • Walgreens - 215 Beach St - Malden

Trial Details

FieldValue
Enrollment Target 2,660 participants
Start Date 2024-10-19
Est. Completion 2026-05
Biomedical Advanced Research and Development Authority

10 total trials

What the registry record for NCT06761612 still lists

NCT06761612 is an observational study that tracks outcomes without assigning an intervention. Its 2,660 participants enrollment target places it among the larger protocols in the corpus, below the 38,456-participant average among 298 other COVID-19 trials with a reported enrollment target (93% lower).

The record links to 1 condition, with COVID-19 appearing as the primary indexed condition, and to 1 intervention - of which FDA approved mRNA vaccines is the first listed.

NCT06761612 names 20 study sites across 8 states, led by Texas, Illinois, Missouri.

Frequently Asked Questions

What is clinical trial NCT06761612 about?

NCT06761612 is a clinical study titled "Retail COVID-19 Study". Despite the availability of vaccines, there remains a need to identify specific immune responses that correlate with protection against SARS-CoV-2 infection. Additionally, the operational capability of retail pharmacy infrastructure to collect longitudinal data and biological samples needs to be ass...

What is the current status of trial NCT06761612?

This trial is currently active not recruiting. The enrollment target is 2,660 participants. The study started on 2024-10-19. Estimated completion is 2026-05.

What conditions does trial NCT06761612 study?

This clinical trial studies the following conditions: COVID-19.

What interventions are being tested in trial NCT06761612?

The interventions under investigation include: FDA approved mRNA vaccines (BIOLOGICAL).

Who is sponsoring clinical trial NCT06761612?

This trial is sponsored by Biomedical Advanced Research and Development Authority, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06761612 being conducted?

This trial has 20 study locations across Florida, Illinois, Kansas, Massachusetts, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for COVID-19

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06761612's enrollment target sits among peer trials

2,660 39th of 298 higher than 260 of 298 other COVID-19 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other COVID-19 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06825715 · 2,653 participants · NA

    Multilevel Intervention for Precision Oncology

  • NCT05471908 · 2,674 participants · NA

    Follow-up Automatically vs. As-Needed Comparison (FAAN-C) Trial

  • NCT06455085 · 2,634 participants · NA

    RESTORE: REducing Future fractureS and Improving ouTcOmes of fRagility fracturE

  • NCT05111925 · 2,690 participants

    Pre- and Post-neuromusculoskeletal Injury Risk Evaluation for Return-to-Duty Enhancement

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT06761612, the US trial registry maintained by the National Library of Medicine. NCT06761612 (large enrollment · wide site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.